References
Dombrowski S, Kostev K, Jacob L (2017) Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—a retrospective analysis of real-world data. Osteoporos Int. doi:10.1007/s00198-017-4051-y
Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I (2016) DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes—a systematic review and meta-analysis. Diabetes Res Clin Pract 116:288–298
Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A et al (2015) Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care 38(11):2142–2150
Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19(3):421–428
Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16(3):241–249
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
JD, LK, PG and JvB declare that they have no conflicts of interest.
Additional information
A response to these comments can be found at doi:10.1007/s00198-017-4139-4.
Rights and permissions
About this article
Cite this article
Driessen, J.H.M., Knapen, L.M., Geusens, P.P.M.M. et al. Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?. Osteoporos Int 28, 2429–2430 (2017). https://doi.org/10.1007/s00198-017-4120-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-017-4120-2